02:11 PM EST, 12/31/2024 (MT Newswires) -- Emil D Kakkis, Director, President & CEO, on December 30, 2024, sold 11,727 shares in Ultragenyx Pharmaceutical ( RARE ) for $495,231. Following the Form 4 filing with the SEC, Kakkis has control over a total of 2,748,590 shares of the company, with 564,605 shares held directly and 2,183,985 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1515673/000095017024141485/xslF345X05/ownership.xml

Price: 41.77, Change: -0.50, Percent Change: -1.18